Intelligence Feed event · Equity · 2026-09-25

    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17

    Question

    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17

    Direct answer

    ADARx Pharmaceuticals, a clinical-stage biotech developing siRNA therapeutics, successfully priced an upsized public listing raising $446.3 million in gross proceeds. The company will list on Nasdaq under the ticker ADRX on September 25. The upsized transaction reflects viable primary equity capital availability for clinical-stage biotechnology assets despite recent macro and rate headwinds.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-25
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17”, revision 1, evidence through 2026-09-25. https://marketontology.com/market-events/2026-09-25/adarx-pharmaceuticals-prices-upsized-446-3m-initial-public-offering-at-17-86f453

    EQUITY
    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
    ADARx Pharmaceuticals, a clinical-stage biotech developing siRNA therapeutics, successfully priced an upsized public listing raising $446.3 million in gross proceeds. The company will list on Nasdaq under the ticker ADRX on September 25. The upsized transaction reflects viable primary equity capital availability for clinical-stage biotechnology assets despite recent macro and rate headwinds.
    ADRXXBI
    Impact
    72
    SEP 25
    SIG
    92%
    ADRXXBI
    ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
    ADARx Pharmaceuticals, a clinical-stage biotech developing siRNA therapeutics, successfully priced an upsized public listing raising $446.3 million in gross proceeds. The company will list on Nasdaq under the ticker ADRX on September 25. The upsized transaction reflects viable primary equity capital availability for clinical-stage biotechnology assets despite recent macro and rate headwinds.
    → Upsized biotech issuance injects $446.3M into clinical siRNA pipeline funding, providing a fresh pricing benchmark for late-stage biotech IPO demand.
    Impact
    ADARx Pharmaceuticals, a clinical-stage biotech developing siRNA therapeutics, successfully priced an upsized public listing raising $446.3 million in gross proceeds. The company will list on Nasdaq under the ticker ADRX on September 25. The upsized transaction reflects viable primary equity capital availability for clinical-stage biotechnology assets despite recent macro and rate headwinds.
    Affected
    ADRXXBI
    Transmission
    Upsized biotech issuance injects $446.3M into clinical siRNA pipeline funding, providing a fresh pricing benchmark for late-stage biotech IPO demand.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    ADRXnasdaq public listing and capital raise liquidityUpintradayPriced upsized IPO at $17/share generating $446.3M gross proceeds.
    XBIbiotech equity primary market issuance momentumUp1-5dSuccessful large-scale biotech IPO issuance provides sentiment support for the sector.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XBIUpdisagreed155.03 2026-09-25+1.02%-0.39%Pending
    ADRXUpdisagreed19.35 2026-09-25+3.82%-5.68%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month